Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | RHEB | Q15382 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107096 | 0.87 | MRGPRX4 (0.41) | LTA4HMRGPRX4CYP4F2CYP4A11FFAR4 | |
| SCHEMBL14667748 | 0.86 | LTA4H (0.52) | LTA4HNR1H2NR1H3CYP4F2CYP4A11 | |
| SCHEMBL22185418 | 0.84 | SMN1; SMN2 (0.43) | MRGPRX4FFAR4LMNAGFERKMT2A | |
| SCHEMBL5125208 | 0.84 | LTA4H (0.57) | LTA4HCYP4F2CYP4A11FFAR4TTR | |
| SCHEMBL9900458 | 0.83 | MRGPRX4 (0.40) | MRGPRX4FFAR4LMNAGFERKMT2A | |
| SCHEMBL257919 | 0.80 | TEAD4 (0.48) | MRGPRX4LMNAGFERKMT2AL3MBTL1 | |
| SCHEMBL14661841 | 0.79 | LTA4H (0.52) | LTA4HNR1H2NR1H3PPARGTTR | |
| SCHEMBL715391 | 0.79 | CYP4F2 (0.46) | MRGPRX4CYP4F2CYP4A11FFAR4KMT2A | |
| SCHEMBL28061160 | 0.78 | LTA4H (0.48) | LTA4HFFAR4LMNAKMT2AL3MBTL1 | |
| SCHEMBL15075246 | 0.78 | LTA4H (0.48) | LTA4HMRGPRX4NR1H2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103827118-B | Bicyclic pyrimidin ketone compound | GLAXO GROUP LTD. (GB) | 2016-03-09 | — | — | CN | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2736908-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | Glaxo Group Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | LTA4H 24/4885MRGPRX4 822/4885NR1H2 1416/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | LTA4H 44/4885MRGPRX4 680/4885NR1H2 297/4885 |
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | LTA4H 14/4885MRGPRX4 771/4885NR1H2 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.